CD274 and melanoma: Prospective evaluation of candidate cancer treatment using ex vivo differentiated MDSCs highlights therapies with significant therapeutic potential and the therapy of the IL12-encoding combined with PD-L1 silencing lentivector vaccines demonstrated promising anti-melanoma activities.